Sanofi pays €120M to buy into AstraZeneca RSV program Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs...
Find MoreWith $496M CNS sale, Novartis joins other Pharma companies casting off tired meds The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs, including Ritalin for attention deficit disorder and Exelon patch for Alzheimer’s. The p...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.